US HIFU, LLC, introduces a new software component, called Tissue Change Monitoring (TCM), to its Sonablate(R) 500 medical device that will enhance its existing minimally invasive treatment for prostate cancer using HIFU, high intensity focused ultrasound, by enabling physicians to monitor prostatic tissue changes in real-time. Stephen Puckett, Jr., chief executive officer, US HIFU said, “TCM represents yet another major step forward for the Sonablate(R) HIFU platform.
Home » US HIFU Announces Addition Of Tissue Change Monitoring (TCM) Software To Sonablate(R) 500 Medical Device
More recent news
- Neuronetics names Steven Pfanstiel chief financial officer
- Medtronic to distribute Future Medical’s peripheral guidewires
- AtriCure completes enrollment in stroke prevention trial
- GT Medical raises $53M to support brain tumor treatment
- Imperative Care, Proximie partner to develop surgical robot to treat stroke